Compare Amgen, Inc. (AMGN) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Procter & Gamble Co — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Procter & Gamble Co trades at $148.32 (market cap $342.40B). The key difference: Procter & Gamble Co is the larger of the two by market cap, and Procter & Gamble Co pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| AMGN | PG | |
|---|---|---|
Market Cap | $196.12B | $342.40B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $167.18 |
52-Week Low | $271.18 | $138.10 |
Enterprise Value | $241.41B | $367.88B |
Dividend Yield | 2.77% | 2.9% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Procter & Gamble (PG) trades at $148.37, up 0.9% today, near the analyst consensus price target of $159.75. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.42. Technical indicators signal a bearish trend, but fundamentals remain solid with $84.28B in revenue and a net income margin of 19.16% in 2025. Recent news highlights PG's dividend reliability and supply chain improvements.
PG offers stable growth with a strong dividend history, but premium valuations and modest revenue growth pose risks. Analyst sentiment is bullish with 53.85% buy ratings, though technical weakness suggests near-term caution. Key catalysts include upcoming earnings and dividend payments, while macroeconomic pressures and competitive threats are headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
